Summary
0JDK Chart
Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman
SAN FRANCISCO, June 18, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class-action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Click Here
Iovance Biotherapeutics, Inc. Dividends
Iovance Biotherapeutics, Inc. Earnings
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
Iovance Biotherapeutics, Inc. (0JDK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Iovance Biotherapeutics, Inc. ever had a stock split?
Iovance Biotherapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Frederick G. Vogt Esq., J.D., Ph.D. CEO | LSE Exchange | US4622601007 ISIN |
| US Country | 838 Employees | - Last Dividend | 26 Sep 2013 Last Split | 15 Oct 2010 IPO Date |
Overview
Iovance Biotherapeutics, Inc. stands as a commercial-stage biotechnology entity dedicated to developing and commercializing innovative cell therapies. Utilizing autologous tumor infiltrating lymphocyte technology, the company aims to provide treatments for metastatic melanoma alongside other solid tumor cancers within the United States. Originating in 2007 and originally known as Lion Biotechnologies, Inc., the company transitioned to its current name in June 2017. With its headquarters in San Carlos, California, Iovance Biotherapeutics has established numerous strategic collaborations and licensing agreements with prominent institutions and companies across the healthcare and biotechnology sectors. These partnerships extend to WuXi Advanced Therapies, Inc.; National Institutes of Health; National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH, aiming to enhance its offering and impact in cancer treatment.
Products and Services
- Amtagvi
Described as a pioneering tumor-derived autologous T cell immunotherapy, Amtagvi is specifically designed for adult patients struggling with unresectable or metastatic melanoma. This product marks Iovance's commitment to offering advanced therapeutic options that leverage the body's immune system to fight cancer.
- Proleukin
An interleukin-2 product, Proleukin serves as a treatment solution for patients with metastatic renal cell carcinoma. Through boosting the patient's immune response, it aims at attacking and eliminating cancer cells, underscoring the company's expertise in immunotherapy.
- Lifileucel in combination with pembrolizumab
This development focuses on treating frontline advanced melanoma patients by combining lifileucel with pembrolizumab. The strategic integration of these treatments exemplifies Iovance's innovative approach towards providing comprehensive care for melanoma patients.
- LN-145
Targeted at addressing the challenges in non-small cell lung cancer (NSCLC) and other solid tumor cancers, LN-145 is an ongoing project that aims to expand the therapeutic reach of the company’s immunotherapy solutions.
- IOV-4001
Currently in Phase 1/2 IOV-GM1-201 clinical trial, IOV-4001 represents Iovance's commitment to innovating treatment options for NSCLC. This exploration into new therapies highlights the company’s dedication to contributing significant advancements in cancer treatment.
- Lifileucel for Gynecological Cancers
Another pivotal area of development, the application of lifileucel for treating gynecological cancers, signifies Iovance's broader endeavor to tackle a variety of cancer types with its cell therapy technologies.
Contact Information
